News and Press Releases
Press releases
Theralase Brain Cancer Pre-Clinical Research Accepted for Publication
Research Detailing Advantages of Rutherrin® PhotoDynamic Therapy in deadly brain cancer, GlioBlastoma Multiforme (“GBM”) to be Published in th...
0Theralase® Releases 2018 Year End Audited Financial Statements
Toronto, Ontario – April 17, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical ...
0Theralase Releases Amended and Restated 1Q2019 Financial Statements
Toronto, Ontario – June 18, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage p...
0Theralase Releases 1Q2019 Financial Statements
Toronto, Ontario – May 30, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stag...
0Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
Toronto, Ontario – May 20, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stag...
0Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Toronto, Ontario – May 13, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stag...
0Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Toronto, Ontario – May 7, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
0Theralase’s Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association
Toronto, Ontario – May 6, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
0Theralase Commences Phase II NMIBC Clinical Study
Toronto, Ontario – April 25, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stag...
0Theralase’s Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress
Nine Scientific Papers Detailing the Latest Scientific Research of Theralase®’s Anti-Cancer Technology (“ACT”) Platform have been Peer Revie...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.